It also describes an Antibody that binds specifically to the Human EPO receptor, in which the Antibody binds to the Fragment of the EPO receptor (lpgpggsvdiv id. sec. No. 01) but not specifically binds to a Protein that can be obtained from human endothelial cells that has a Molecular Weight of about 66 KD.Claim 1: an in vitro method for the detection of the Human EPO receptor that includes the following steps: determining the presence of in vitro Human EPO receptor in a sample by Incubation of the sample with an Antibody against the EPO receptor that binds d And the specific Fragment of the Human EPO receptor lpgpggsvdiv (id. sec.No. 01) and detected in vitro Human EPO receptor, in which the EPO Receptor Antibody that binds specifically to the Fragment of the EPO receptor (lpgpggsvdiv id. sec. No. 01) specifically binds to a Protein that can be obtained from human endothelial cells and has a Molecular Weight of about 66 KD.Claim 5: the use of an Antibody that binds specifically to the Human EPO receptor, which is characterized in that the Antibody binds to the Fragment of the EPO receptor (lpgpggsvdiv id. sec.No. 01) and not specifically binds to a Protein that can be obtained from human endothelial cells and has a Molecular Weight of about 66 KD, to detect the Human EPO receptor. Claim 13: a Pharmaceutical formulation comprising the Antibody of any of Claims 2 to 4 and a pharmaceutically acceptable Carrier.Claim 14: an isolated Nucleic Acid encoding the Antibody according to any of Claims 2 to 4. Claim 15: a host Cell comprising the Nucleic Acid of claim 14.Claim 17: the use of an Antibody according to any of Claims 2 to 4 for the analysis of EPO receptor in a sample of Human tissue or cell.Describe también un anticuerpo que se une de forma especifica al receptor de la EPO humano, en el que el anticuerpo se une al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) pero no se une específicamente a una proteína que puede obtenerse a partir de células e
